407 Preliminary safety, pharmacokinetics/pharmacodynamics, and antitumor activity of XmAb20717, a PD-1 x CTLA-4 bispecific antibody, in patients with advanced solid tumors
Elaine Shum, Adil Daud, Matthew Reilley, Yana Najjar, John Thompson, Joaquina Baranda, R Donald Harvey, Rom Leidner, Anthony Shields, Ezra Cohen, Roger Cohen, Alain Mita, Shubham Pant, Mark Stein, Bartosz Chmielowski, Siwen Hu-Lieskovan, Catherine Fleener, Ying Ding, Sowmya Chollate, Hector Avina, Jolene Shorr, Raphael Clynes, Barbara Hickingbottom
Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A247-A248; DOI: 10.1136/jitc-2020-SITC2020.0407